Dexamphetamine modulation of brainwave activity and prepulse inhibition in healthy participants

Not Applicable

Recruiting

• Conditions: Schizophrenia; Mental Health - Studies of normal psychology, cognitive function and behaviour

• Registration Number: ACTRN12608000610336
• Lead Sponsor: Mathew Martin-Iverson

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-12-05
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

healthy

Exclusion Criteria

1. Pregnancy or currently breastfeeding
2. hearing disorders
3. neurological disorders or known seizure risk
4. history of loss of consciousness for over 15 min
5. current diagnosis or treatment for a mental illness
6. past or current treatment for substance use disorder
7. significant risk of psychosis
8. presence or history of a kinetic disorder
9. presence or history of hypertension
10. presence or history of hepatic insufficiency
11. presence renal insufficiency
12. presence or history of cardiovascular disorder
13. significant risk of suicide
14. known hypersensitivity to amphetamines
15. receiving any systemic prescription medication (excluding contraceptives)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prepulse Inhibition of the Acoustic Startle Response[90-120 min];Change in P300 Event-Related Potential (EEG)[210 min]

Secondary Outcome Measures

Name	Time	Method
Saliva dexamphetamine level[0, 90, 150, 240, 300 min];Plasma dexamphetamine level[90 min]